Across TCGA pan-cancer cohorts, C16orf54 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C16orf54 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher C16orf54 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated C16orf54 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM, LUAD, and LSCC are the cancer types where C16orf54 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.594	0.214	.001	15	view →
LUAD	OS	Median	III,IV	0.819	0.341	.034	4	view →
LSCC	DFS	Median	II,III,IV	0.519	0.851	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: C16orf54 tumor-vs-normal RNA expression · all C16orf54 data types